uses cookies to analyze how the website is used, and to improve the user experience. Read more about cookies

Decision to fine Leadiant for excessive price of CDCA drug

After an investigation ACM has determined that manufacturer Leadiant abused its dominant position by charging an excessive price for its prescription drug. CDCA-Leadiant. This occurred in the period from June 2017 through December 2019. For this violation ACM has imposed a fine on Leadiant of 19,569,500 euros.

Here you can find the summary of the decision. The public version of the full decision will be published at a later date.



Summary of decision on abuse of dominant position by Leadiant (PDF - 180.87 KB)